Zenith Drugs Limited (NSE:ZENITHDRUG)

Zenith Drugs Statistics

Total Valuation

Zenith Drugs has a market cap or net worth of INR 1.08 billion. The enterprise value is 1.57 billion.

Market Cap	1.08B
Enterprise Value	1.57B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Zenith Drugs has 17.15 million shares outstanding. The number of shares has increased by 42.91% in one year.

Current Share Class	17.15M
Shares Outstanding	17.15M
Shares Change (YoY)	+42.91%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	69.98%
Owned by Institutions (%)	n/a
Float	5.15M

Valuation Ratios

The trailing PE ratio is 15.15.

PE Ratio	15.15
Forward PE	n/a
PS Ratio	0.81
PB Ratio	1.56
P/TBV Ratio	1.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.06, with an EV/FCF ratio of -4.26.

EV / Earnings	21.89
EV / Sales	1.18
EV / EBITDA	11.06
EV / EBIT	13.98
EV / FCF	-4.26

Financial Position

The company has a current ratio of 1.45, with a Debt / Equity ratio of 0.70.

Current Ratio	1.45
Quick Ratio	0.77
Debt / Equity	0.70
Debt / EBITDA	3.43
Debt / FCF	-1.32
Interest Coverage	5.14

Financial Efficiency

Return on equity (ROE) is 10.88% and return on invested capital (ROIC) is 6.87%.

Return on Equity (ROE)	10.88%
Return on Assets (ROA)	4.74%
Return on Invested Capital (ROIC)	6.87%
Return on Capital Employed (ROCE)	13.65%
Revenue Per Employee	7.33M
Profits Per Employee	393,440
Employee Count	182
Asset Turnover	0.90
Inventory Turnover	2.68

Taxes

In the past 12 months, Zenith Drugs has paid 21.00 million in taxes.

Income Tax	21.00M
Effective Tax Rate	22.68%

Stock Price Statistics

The stock price has decreased by -19.17% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-19.17%
50-Day Moving Average	66.81
200-Day Moving Average	73.07
Relative Strength Index (RSI)	44.31
Average Volume (20 Days)	8,160

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zenith Drugs had revenue of INR 1.33 billion and earned 71.61 million in profits. Earnings per share was 4.18.

Revenue	1.33B
Gross Profit	456.78M
Operating Income	112.13M
Pretax Income	92.61M
Net Income	71.61M
EBITDA	141.80M
EBIT	112.13M
Earnings Per Share (EPS)	4.18

Balance Sheet

The company has 2.63 million in cash and 485.68 million in debt, giving a net cash position of -483.05 million or -28.17 per share.

Cash & Cash Equivalents	2.63M
Total Debt	485.68M
Net Cash	-483.05M
Net Cash Per Share	-28.17
Equity (Book Value)	693.79M
Book Value Per Share	40.46
Working Capital	358.74M

Cash Flow

In the last 12 months, operating cash flow was -54.66 million and capital expenditures -313.08 million, giving a free cash flow of -367.74 million.

Operating Cash Flow	-54.66M
Capital Expenditures	-313.08M
Free Cash Flow	-367.74M
FCF Per Share	-21.44

Margins

Gross margin is 34.26%, with operating and profit margins of 8.41% and 5.37%.

Gross Margin	34.26%
Operating Margin	8.41%
Pretax Margin	6.95%
Profit Margin	5.37%
EBITDA Margin	10.64%
EBIT Margin	8.41%
FCF Margin	n/a

Dividends & Yields

Zenith Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-42.91%
Shareholder Yield	-42.91%
Earnings Yield	6.60%
FCF Yield	-33.90%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zenith Drugs has an Altman Z-Score of 2.45 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.45
Piotroski F-Score	4